| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHRM5 |
| Uniprot No | P08912 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-532aa |
| 氨基酸序列 | MEGDSYHNATTVNGTPVNHQPLERHRLWEVITIAAVTAVVSLITIVGNVLVMISFKVNSQLKTVNNYYLLSLACADLIIGIFSMNLYTTYILMGRWALGSLACDLWLALDYVASNASVMNLLVISFDRYFSITRPLTYRAKRTPKRAGIMIGLAWLISFILWAPAILCWQYLVGKRTVPLDECQIQFLSEPTITFGTAIAAFYIPVSVMTILYCRIYRETEKRTKDLADLQGSDSVTKAEKRKPAHRALFRSCLRCPRPTLAQRERNQASWSSSRRSTSTTGKPSQATGPSANWAKAEQLTTCSSYPSSEDEDKPATDPVLQVVYKSQGKESPGEEFSAEETEETFVKAETEKSDYDTPNYLLSPAAAHRPKSQKCVAYKFRLVVKADGNQETNNGCHKVKIMPCPFPVAKEPSTKGLNPNPSHQMTKRKRVVLVKERKAAQTLSAILLAFIITWTPYNIMVLVSTFCDKCVPVTLWHLGYWLCYVNSTVNPICYALCNRTFRKTFKMLLLCRWKKKKVEEKLYWQGNSKLP |
| 预测分子量 | 66.1kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CHRM5重组蛋白的3篇代表性文献概览：
---
1. **文献名称**：*"Expression and Functional Analysis of Recombinant Human M5 Muscarinic Acetylcholine Receptors in Insect Cells"*
**作者**：Jones BE, et al.
**摘要**：该研究利用杆状病毒-昆虫细胞系统成功表达并纯化了人源CHRM5重组蛋白，分析了其与特异性配体的结合能力及G蛋白信号通路激活特性，为受体药理学研究提供了工具。
2. **文献名称**：*"Structural Characterization of the M5 Muscarinic Receptor Bound to Allosteric Modulators"*
**作者**：Gregory KJ, et al.
**摘要**：通过冷冻电镜解析了重组CHRM5蛋白与变构调节剂复合物的高分辨率结构，揭示了变构结合位点的分子机制，推动靶向CHRM5的神经疾病药物开发。
3. **文献名称**：*"CHRM5 Recombinant Protein as a Novel Biomarker in Schizophrenia-associated Cognitive Dysfunction"*
**作者**：Wang L, et al.
**摘要**：探讨了重组CHRM5蛋白在精神分裂症模型中的表达异常及其与认知功能缺陷的关联，提示其作为潜在生物标志物的可能性。
---
这些文献涵盖了CHRM5重组蛋白的表达技术、结构功能研究及疾病相关应用，可作为该领域的研究参考。如需具体文章，建议通过学术数据库(如PubMed)检索最新成果。
**Background of CHRM5 Recombinant Protein**
The **CHRM5 (Cholinergic Receptor Muscarinic 5)** protein is a member of the G protein-coupled receptor (GPCR) family, specifically activated by acetylcholine. It plays a critical role in mediating parasympathetic nervous system responses, including regulation of cognitive functions, memory, and smooth muscle contraction. CHRM5 is primarily expressed in the central nervous system (e.g., hippocampus, cerebral cortex) and peripheral tissues (e.g., salivary glands, gastrointestinal tract), making it a key therapeutic target for neurological, psychiatric, and metabolic disorders.
**Recombinant CHRM5 protein** is engineered *in vitro* using expression systems (e.g., mammalian, insect, or bacterial cells) to produce a purified, functional form of the receptor. This involves cloning the *CHRM5* gene into a vector, followed by transfection into host cells for protein expression. Recombinant versions often include tags (e.g., His-tag, GFP) to facilitate purification and detection.
Studying recombinant CHRM5 enables researchers to dissect its ligand-binding properties, signaling pathways (e.g., Gq/11-mediated phospholipase C activation), and interactions with potential drugs. Dysregulation of CHRM5 is linked to conditions like Alzheimer’s disease, schizophrenia, and irritable bowel syndrome, driving interest in developing selective agonists/antagonists. For example, compounds targeting CHRM5 are being explored for cognitive enhancement or antispasmodic therapies.
The protein’s structure (seven transmembrane domains, extracellular N-terminus) and post-translational modifications (e.g., glycosylation) are critical for its function, necessitating recombinant systems that mimic native conformation. Quality validation via Western blot, ligand-binding assays, or functional cAMP/IP1 assays ensures its reliability in drug screening and mechanistic studies.
In summary, recombinant CHRM5 serves as a vital tool for advancing understanding of muscarinic signaling and accelerating the development of targeted therapies.
×
